...
首页> 外文期刊>Critical reviews in oncology/hematology >Can first cycle CBCs predict older patients at very low risk of neutropenia during further chemotherapy?
【24h】

Can first cycle CBCs predict older patients at very low risk of neutropenia during further chemotherapy?

机译:第一周期CBC能否预测在进一步化疗期间中性粒细胞减少症风险很低的老年患者?

获取原文
获取原文并翻译 | 示例
           

摘要

Elderly cancer patients with normal complete blood cell counts (CBCs) during the first course of (some types of) chemotherapy might be unlikely to experience grade 4 neutropenia during subsequent cycles. In this case, further weekly CBCs might be avoided. We used data of 223 cancer patients aged 70+ who were included in the CRASH (Chemotherapy Risk Assessment Score for High-age patients) trial between 2003 and 2007 in 7 cancer practices in the US. First cycle CBC values were compared to subsequent cycles. MAX2-score was used as a measure for toxicity of the chemotherapy regimen. Sixty-two patients (28%) experienced grade 4 neutropenia during subsequent cycles. Among patients who received chemotherapy with a MAX2-score lower than 0.20, only 4.6% of those without neutropenia during the first cycle experienced grade 4 neutropenia during subsequent cycles. Weekly CBC might be avoided in these patients receiving chemotherapy. Future prospective studies should confirm these results.
机译:在化疗(某些类型)的第一个疗程中具有正常全血细胞计数(CBC)的老年癌症患者,在随后的周期中不太可能会经历4级中性粒细胞减少。在这种情况下,可以避免进一步的每周CBC。我们使用了2003年至2007年间在美国7种癌症实践中纳入CRASH(高龄患者的化学疗法风险评估得分)试验的223位70岁以上的癌症患者的数据。将第一周期的CBC值与随后的周期进行比较。 MAX2-评分被用作化学疗法方案毒性的量度。 62名患者(28%)在随后的周期中经历了4级中性粒细胞减少。在接受MAX2评分低于0.20的化疗的患者中,只有4.6%的患者在第一个周期无中性粒细胞减少,而在随后的周期中出现4级中性粒细胞减少。这些接受化疗的患者可避免每周CBC。未来的前瞻性研究应证实这些结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号